The proform of eosinophil major basic protein: a new maternal serum marker for adverse pregnancy outcome

2009 ◽  
Vol 29 (11) ◽  
pp. 1013-1019 ◽  
Author(s):  
Kasper Pihl ◽  
Torben Larsen ◽  
Steen Rasmussen ◽  
Lone Krebs ◽  
Michael Christiansen
Keyword(s):  
Pregnancy Outcome ◽  
Basic Protein ◽  
Adverse Pregnancy Outcome ◽  
Protein A ◽  
Serum Marker ◽  
Maternal Serum ◽  
Major Basic Protein ◽  
Adverse Pregnancy ◽  
Eosinophil Major Basic Protein

The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome

1999 ◽  
Vol 19 (10) ◽  
pp. 905-910 ◽  
Author(s):  
Michael Christiansen ◽  
Claus Oxvig ◽  
Jill M. Wagner ◽  
Qiu-Ping Qin ◽  
Tri H. Nguyen ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Basic Protein ◽  
Protein A ◽  
Serum Marker ◽  
Maternal Serum ◽  
Major Basic Protein ◽  
Eosinophil Major Basic Protein

Second trimester maternal serum marker and adverse pregnancy outcome

2011 ◽  
Vol 54 (11) ◽  
pp. 651 ◽  
Author(s):  
Se-Eun Cho ◽  
Yoo Jeong Shin ◽  
Hyo Jeong Kim ◽  
Hyun-Young Ji ◽  
Hye-Min Kwak ◽  
...  
Keyword(s):  
Pregnancy Outcome ◽  
Adverse Pregnancy Outcome ◽  
Serum Marker ◽  
Maternal Serum ◽  
Second Trimester ◽  
Adverse Pregnancy

scholarly journals Quantification of Proteolytically Active Pregnancy-Associated Plasma Protein-A with an Assay Based on Quenched Fluorescence

2007 ◽  
Vol 53 (5) ◽  
pp. 947-954 ◽  
Author(s):  
Claus Gyrup ◽  
Michael Christiansen ◽  
Claus Oxvig
Keyword(s):  
Proteolytic Activity ◽  
Plasma Protein ◽  
Basic Protein ◽  
Biological Function ◽  
Limit Of Detection ◽  
Protein A ◽  
Maternal Serum ◽  
Serum Samples ◽  
A Subunit ◽  
Eosinophil Major Basic Protein

Abstract Background: Maternal serum concentrations of pregnancy-associated plasma protein-A (PAPP-A, pappalysin-1, EC 3.4.24.79) are used to predict the occurrence of Down syndrome. In pregnancy, PAPP-A primarily circulates as a covalent 2:2 complex with the proform of eosinophil major basic protein (proMBP), which inhibits the proteolytic activity of PAPP-A. At term, however, ∼1% of PAPP-A exists as an active, uncomplexed dimer with proteolytic activity directed specifically toward insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5. No assays have been developed that allow quantification of PAPP-A proteolytic activity. Methods: We developed a sensitive and specific immunocapture assay for PAPP-A activity based on intramolecular quenched fluorescence. We used a 26-residue synthetic peptide derived from IGFBP-4 in which specific positions on each side of the PAPP-A cleavage site were substituted with 3-nitrotyrosine and o-aminobenzoic acid. Results: The assay detected the activity of recombinant PAPP-A as well as PAPP-A in serum samples from pregnant women. The limit of detection (mean signal of blank plus 3 SD) of the active PAPP-A subunit was 13 pmol/L, and the intra- and interassay CVs were <10% and <15%, respectively. Interestingly, the fraction of active PAPP-A decreased gradually from week 7 to week 19 of pregnancy. Conclusions: This method allows the measurement of PAPP-A enzymatic activity and because of its specificity it is relevant to the study of the biological function of PAPP-A. The method may also be useful in the diagnosis of pregnancy disorders.

The effect of fetomaternal bleeding on the risk of adverse pregnancy outcome in patients with elevated second-trimester maternal serum α-fetoprotein levels

1994 ◽  
Vol 171 (2) ◽  
pp. 315-320 ◽  
Author(s):  
James T. Christmas ◽  
Lauren V. Vanner ◽  
Robert M. Daniels ◽  
Joanne N. Bodurtha ◽  
Patricia M. Hays ◽  
...  
Keyword(s):  
Pregnancy Outcome ◽  
Adverse Pregnancy Outcome ◽  
Maternal Serum ◽  
Second Trimester ◽  
Adverse Pregnancy
Sign in / Sign up

Export Citation Format

Share Document